ISIgnacio Smith

Ignacio Smith

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ignacio Smith has a total of 9 co-authors. Here are the top co-authors by number of shared publications:

  • Ana Carolina Mourelle

    Universidad de Buenos Aires (UBA), Facultad de Farmacia y Bioquímica, Departamento de Microbiología, Inmunología, Biotecnología y Genética, Cátedra de Inmunología, Junín 956, C1113AAD Buenos Aires, Argentina

    1 shared publication
  • Federico Javier Wolman

    Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Junín 956, Buenos Aires C1113AAD, Argentina

    1 shared publication
  • Juan Ignacio Marfía

    Universidad de Buenos Aires (UBA), Facultad de Farmacia y Bioquímica, Departamento de Microbiología, Inmunología, Biotecnología y Genética, Cátedra de Inmunología, Junín 956, C1113AAD Buenos Aires, Argentina

    1 shared publication
  • Leonardo Gabriel Alonso

    Universidad de Buenos Aires (UBA), Facultad de Farmacia y Bioquímica, Departamento de Microbiología, Inmunología, Biotecnología y Genética, Cátedra de Biotecnología, Junín 956, C1113AAD Buenos Aires, Argentina

    1 shared publication
  • María Lina Formica

    Unidad de Investigación y Desarrollo en Tecnología Farmacéutica (UNITEFA), CONICET, Departamento de Ciencias Farmacéuticas, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Ciudad Universitaria, Córdoba 5000, Argentina

    1 shared publication
  • María Victoria Miranda

    Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires, Argentina, Argentina

    1 shared publication

Latest Publications

  • Open Access

    Cooperative supramolecular integration of QS-21 into polymeric micelles as a tunable nanoadjuvant platform for subunit vaccines

    by Patricio Guillermo Márquez, Leonardo Gabriel Alonso, Juan Ignacio Marfía, Ignacio Smith, Ana Carolina Mourelle, María Lina Formica, María Victoria Miranda, Silvina Noemí Valdez, Federico Javier Wolman, Romina Julieta Glisoni

    Potent saponin adjuvants such as QS-21, used in clinically approved vaccine formulations, remain limited by intrinsic hemolytic activity and restricted aqueous stability, motivating biomaterials strategies aimed at regulating their interfacial behavior while preserving immunostimulatory function. Here, we show that when combined with amphiphilic PEO–PPO triblock copolymers (P123 and F127), QS-21 appears to participate in cooperative supramolecular integration into polymeric micelles rather than behaving as a passively encapsulated cargo. This architecture-dependent organization gives rise to structurally coherent nanosystems with enhanced dilution stability and controlled membrane activity. Comparative analysis revealed that P123/QS-21 assemblies form compact, monodisperse micelles (∼21 nm) with marked resistance to dilution, whereas F127-based systems display greater structural heterogeneity and reduced supramolecular robustness. Cooperative integration is associated with attenuation of hemolytic activity in a concentration-dependent manner relative to free QS-21 while preserving functional accessibility, consistent with controlled interfacial presentation of the saponin. These physicochemical features are supported by DLS, TEM, and NTA analyses. In vivo evaluation using a SARS-CoV-2 Spike subunit antigen indicates that P123/QS-21 is associated with enhanced systemic and mucosal antibody responses while inducing functional neutralizing activity. Together, these findings support cooperative supramolecular integration as a biomaterials design principle to modulate membrane activity and nanoadjuvant performance, providing a scalable and tunable framework for the development of subunit vaccine platforms.